KMDA

Interested in Kamada Ltd.? Here are five stocks we like better. Kamada reaffirmed its full-year 2026 outlook for revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, saying first-quarter results were broadly in line with expectations aside from a temporary shipment delay that pushed about $2.4 million of revenue into April. Q1 revenue was $42.5 million, down slightly from $44 million a year ago, while net income held steady at $4.1 million and adjusted EBITDA was unchanged at $11.6 million. Lower gross margin and lower operating expenses reflected a mix shift and reduced R&D spending after ending the InnovAATe trial. Management highlighted growth drivers including KEDRAB, GLASSIA, CYTOGAM, VARIZIG, expanding biosimilar and MENA distribution businesses, and new plasma collection centers. Kamada also said it is pursuing M&A while remaining focused on organic growth and long-term profitable expansion. Kamada (NASDAQ:KMDA) reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that shifted revenue into April. Chief Executive Officer Amir London said demand across the company’s product portfolio continues to support expectations for stronger results over the remainder of the year. Kamada maintained its 2026 guidance for revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million. London said the midpoint of that outlook represents 12% revenue growth and 23% adjusted EBITDA growth compared with 2025 results. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? “Importantly, this 2026 annual guidance is based currently solely on organic growth,” London said. Chief Financial Officer Chaime Orlev said first-quarter revenue was $42.5 million, compared with $44 million in the prior-year period. He said year-over-year revenue performance was primarily driven by increased sales of KEDRAB, Kamada’s anti-rabies immunoglobulin, and higher sales in the company’s distribution segment. → MercadoLibre Boldly Invests in Growth: Discount Deepens Gross profit was $19.1 million, with gross margin of 42%, compared with gross profit of $20.7 million and gross margin of 47% in the first quarter of 2025. Orlev said the lower gross margin reflected product and market sales mix. Operating exp...

This article first appeared on GuruFocus. Total Revenue: $42.5 million for Q1 2026, a 3% increase from $44 million in Q1 2025. Gross Profit: $19.1 million in Q1 2026. Gross Margin: 42% in Q1 2026, compared to 47% in Q1 2025. Operating Expenses: $12.1 million in Q1 2026, down from $13 million in Q1 2025. Net Income: $4.1 million or $0.07 per diluted share in Q1 2026, up 4% from $4 million or $0.07 per diluted share in Q1 2025. Adjusted EBITDA: $11.6 million in Q1 2026, equivalent to Q1 2025. Cash and Cash Equivalents: $73.1 million as of March 31, 2026. Dividend Declared: $0.25 per share, totaling approximately $14.4 million, paid on April 7, 2026. Warning! GuruFocus has detected 3 Warning Signs with ALT. Is KMDA fairly valued? Test your thesis with our free DCF calculator. Release Date: May 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Kamada Ltd (NASDAQ:KMDA) reported first quarter revenues and adjusted EBITDA in line with expectations, despite a temporary shipment delay. The company reiterated its 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, indicating strong growth prospects. Kamada Ltd (NASDAQ:KMDA) is expanding its commercial product portfolio, including six FDA-approved specialty plasma-derived products, supporting organic growth in the U.S. and international markets. The company is launching additional biosimilar products in the Israeli market and expanding its distribution business to the MENA region. Kamada Ltd (NASDAQ:KMDA) received FDA approval for its plasma collection center in San Antonio, Texas, and plans to initiate normal-source plasma sales in the second half of the year. A temporary shipment delay affected first quarter financial results, although the order was delivered in April. Gross margins decreased from 47% in Q1 2025 to 42% in Q1 2026, impacted by product and market sales mix. Operating expenses, including R&D, sales and marketing, and G&A, totaled $12.1 million, reflecting increased investments in commercial growth. Cash and cash equivalents decreased to $73.1 million as of March 31, 2026, from $75.5 million at the end of 2024. The plasma collection centers in Houston and San Antonio are not expected to reach full capacity until the end of 2027 or early 2028. Q: Could you give more color on the reve...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Performance in Q1 was impacted by a $2.4 million temporary shipment delay of a single order due to Middle East flight limitations, though the order was fulfilled in April. Management attributes confidence in 2026 guidance to increasing underlying demand for the core specialty plasma portfolio, particularly KEDRAB and VARIZIG. The company is pursuing a vertical integration strategy by ramping up three plasma centers to reduce specialty plasma costs and generate new revenue from normal source plasma sales. Strategic positioning for CYTOGAM is being reinforced through a post-marketing research program designed to provide clinical data that justifies its use alongside antivirals. The distribution segment is expanding beyond Israel into the MENA region, utilizing a full-service model from registration to commercialization to attract international partners. Growth in the GLASSIA franchise is driven by identifying and diagnosing new patients in highly misdiagnosed international markets like Argentina, Russia, and Switzerland. Reiterated 2026 revenue guidance of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, based currently on organic growth only. Normal source plasma sales from the San Antonio and Houston centers are expected to commence in the second half of 2026 following recent FDA approval. The biosimilar portfolio is projected to reach annual sales of $15 million to $20 million within the next 4 to 5 years as more products enter the Israeli market. Management is actively evaluating M&A and business development opportunities to secure near-term transactions that complement existing commercial operations. Plasma collection centers are expected to reach full planned capacity by late 2027 or early 2028. Gross margin compression to 42% in Q1 was primarily a result of shifts in product and market sales mix. Operating expenses were mitigated by reduced R&D spending following the termination of the Phase III InnovAATe clinical trial. A dividend policy was established to distribute at least 50% of annual net income, reflecting management's confidence in liquidity and future cash flow. Geopolitical factors in the Middle East were cited as a specific risk to logistics and shipment timelin...

Image source: The Motley Fool. Wednesday, May 13, 2026 at 8:30 a.m. ET Chief Executive Officer — Amir London Chief Financial Officer — Chaime Orlev Operator — [Not named, but included for material role in Q&A facilitation] Amir London: Thank you, Brian. Thanks also to our investors and analysts for your interest in Kamada and for participating in today's call. I'm pleased to report that our operational and financial performance in 2026 is off to a solid start. First quarter revenues and adjusted EBITDA were in line with our expectations. Importantly, while a temporary shipment delay of a single order, which was already delivered in April, affected our first quarter financial results, the underlying demand for our products continues to increase, supporting our confidence for significantly stronger results over the remainder of 2026. As such, we are reiterating our 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, respectively, representing 12% and 23% growth percentage when comparing 2026 guidance midpoint to 2025 results. Importantly, this 2026 annual guidance is based currently solely on organic growth. We're excited about the growth prospects of our business over both the near and longer term. Our strategy is focused on the expansion of our entire commercial product portfolio, including continued investment in the commercialization and life cycle management of our 6 FDA-approved specialty plasma-derived products, supporting organic commercial growth in the U.S. as well as in ex U.S. markets. As part of our commercial growth, we also anticipate growing our distribution segment through the launch of additional biosimilar products in the Israeli market as well as the expansion of the distribution business to the MENA region. We further expect to continue ramping up the plasma collection in our three plasma centers, aiming to strengthen our vertical integration, reduce specialty plasma costs and increase revenues through sales of normal source plasma. Lastly, we are focused on securing new business development and M&A transactions, which will enrich our current portfolio of marketed products and generate synergies with our existing commercial operation. I will now expand on each of these strategic growth pillars. Our lead product continues to be our anti-rabies immunoglobulin, KEDRAB, which is b...

REHOVOT, Israel (AP) — REHOVOT, Israel (AP) — Kamada Ltd. (KMDA) on Wednesday reported first-quarter net income of $4.1 million. On a per-share basis, the Rehovot, Israel-based company said it had profit of 7 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 12 cents per share. The biopharmaceutical posted revenue of $45.2 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $46.5 million. Kamada expects full-year revenue in the range of $200 million to $205 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KMDA at https://www.zacks.com/ap/KMDA

• Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter. • CTW Cayman (NASDAQ:CTW) is projected to report earnings for its first quarter. • Milestone Pharmaceuticals (NASDAQ:MIST) is projected to report quarterly earnings at $0.14 per share on revenue of $45.13 million. • Paysafe (NYSE:PSFE) is expected to report quarterly earnings at $0.35 per share on revenue of $424.33 million. • Caesarstone (NASDAQ:CSTE) is projected to report quarterly loss at $0.35 per share on revenue of $97.80 million. • Buda Juice (AMEX:BUDA) is expected to report quarterly earnings at $0.03 per share on revenue of $3.20 million. • Kamada (NASDAQ:KMDA) is expected to report quarterly earnings at $0.12 per share on revenue of $124.20 million. • Kornit Digital (NASDAQ:KRNT) is likely to report quarterly loss at $0.04 per share on revenue of $46.67 million. • Beasley Broadcast Group (NASDAQ:BBGI) is estimated to report earnings for its first quarter. • Xtant Medical Holdings (AMEX:XTNT) is expected to report quarterly loss at $0.02 per share on revenue of $19.79 million. • PDS Biotechnology (NASDAQ:PDSB) is projected to report earnings for its first quarter. • Humacyte (NASDAQ:HUMA) is likely to report quarterly loss at $0.11 per share on revenue of $1.42 million. • Hyatt Hotels (NYSE:H) is likely to report quarterly earnings at $0.63 per share on revenue of $2.33 billion. • Protalix BioTherapeutics (AMEX:PLX) is likely to report quarterly loss at $0.01 per share on revenue of $11.47 million. • Eos Energy Enterprises (NASDAQ:EOSE) is likely to report quarterly loss at $0.24 per share on revenue of $56.41 million. • Riskified (NYSE:RSKD) is likely to report quarterly earnings at $0.02 per share on revenue of $87.64 million. • Aprea Therapeutics (NASDAQ:APRE) is estimated to report earnings for its first quarter. • Immunic (NASDAQ:IMUX) is estimated to report earnings for its first quarter. • Valens Semiconductor (NYSE:VLN) is likely to report quarterly loss at $0.07 per share on revenue of $16.47 million. • DarioHealth (NASDAQ:DRIO) is projected to report quarterly loss at $0.90 per share on revenue of $5.48 million. • Compass Pathways (NASDAQ:CMPS) is likely to report earnings for its first quarter. • Zenas BioPharma (NASDAQ:ZBIO) is expect...

Kamada (KMDA) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -40.02%. A quarter ago, it was expected that this biopharmaceutical would post earnings of $0.09 per share when it actually produced earnings of $0.06, delivering a surprise of -33.33%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Kamada, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $45.24 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 2.63%. This compares to year-ago revenues of $44.02 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Kamada shares have added about 19.4% since the beginning of the year versus the S&P 500's gain of 8.1%. While Kamada has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Kamada was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks h...

On Wednesday, Kamada (NASDAQ:KMDA) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1760803&tp_key=7219e3b56c Kamada reported first-quarter revenues and adjusted EBITDA in line with expectations, despite a temporary shipment delay, and reiterated its 2026 guidance of $200-$205 million in revenues and $50-$53 million in adjusted EBITDA. The company's strategic focus includes expanding its commercial product portfolio, particularly in FDA-approved specialty plasma-derived products, and enhancing its distribution segment with biosimilars in Israel and the MENA region. Operational highlights include FDA approval for a plasma collection center in Texas, plans to launch additional biosimilar products, and ongoing post-marketing research for Cytogam to increase product utilization. Management emphasized strong market demand for key products like Kedrab and Varizig, and noted efforts to secure new business development and M&A opportunities to enhance its portfolio. The company reported a slight increase in net income to $4.1 million and maintained a strong cash position of $73.1 million, while planning continued investments in growth and shareholder dividends. OPERATOR Greetings and welcome to the Kamada Ltd first quarter 2026 earnings conference call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. Should anyone require operator assistance during the conference, please press Star 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Brian Ritchie of LifeSci Advisors. Thank you. You may begin. Brian Ritchie (Host) Thank you, Operator. This is Brian Ritchie with Life Sci Advisors. Thank you all for participating in today's call. Joining me from Kamada are Amir London, Chief Executive Officer and Jaime Orlev, Chief Financial Officer. Earlier today, Kamada announced his financial results for the three months ended March 31, 2026. If you have not received this news release, please go to the Investors page of the company's [email protected]. before we begin, I would l...

Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Demand for the Company’s Products Continues to Increase, Supporting the Company’s Expectation for a Significantly Stronger Remainder of 2026 Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Annual Double-Digit Organic Profitable Growth Q1-2026 Results Impacted by Temporary Shipment Delay of a Single Order, Subsequently Delivered during April Company Continues to Evaluate Near-Term Business Development and M&A Transactions to Further Enhance Long-Term Profitable Growth Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months ended March 31, 2026. “Our operational and financial performance in 2026 is off to a solid start, with first quarter revenues and adjusted EBITDA in line with our expectations,” said Amir London, Kamada’s Chief Executive Officer. “Total revenues for the first quarter were $45.2 million, an increase of approximately 3% year-over-year, and adjusted EBITDA was $11.6 million, representing a robust 26% margin of revenue. Net income for the quarter was $4.1 million, up 4% year-over-year. While temporary shipment delay of a single order, subsequently delivered during April, affected first quarter financial results, importantly, the underlying demand of our products, including for KEDRAB® in the U.S. market as well as KAMRAB® and VARIZIG® in ex-U.S. markets, continues to increase, supporting our confidence for a significantly stronger remainder of 2026. We are reiterating our 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, respectively, representing 12% and 23% growth when comparing 2026 guidance mid-points to 2025 results.” “In 2026, our focus remains on the expansion of our entire commercial product portfolio, including our six FDA-approved specialty plasma-der...

Kamada (KMDA) reported $45.24 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 2.8%. EPS of $0.07 for the same period compares to $0.07 a year ago. The reported revenue represents a surprise of -2.63% over the Zacks Consensus Estimate of $46.46 million. With the consensus EPS estimate being $0.12, the EPS surprise was -40.02%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Kamada performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Distribution: $9.01 million compared to the $4.91 million average estimate based on three analysts. The reported number represents a change of +125.3% year over year. Revenues- Proprietary products: $36.23 million versus the three-analyst average estimate of $41.55 million. The reported number represents a year-over-year change of -9.5%. Gross Profit- Distribution: $1.09 million versus $0.56 million estimated by three analysts on average. Gross Profit- Proprietary products: $18.03 million versus the three-analyst average estimate of $20.26 million. View all Key Company Metrics for Kamada here>>> Shares of Kamada have returned +0.1% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kamada Ltd. (KMDA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Agenus (AGEN) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $2.1 per share. This compares to a loss of $1.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -51.43%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.27 per share when it actually produced earnings of $0.56, delivering a surprise of +144.09%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Agenus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $33.74 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 73.95%. This compares to year-ago revenues of $24.07 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Agenus shares have added about 21.7% since the beginning of the year versus the S&P 500's gain of 8.1%. While Agenus has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Agenus was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks...